Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer-Reference-Cited by-同舟云学术

Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer

Published:2017-08-15 Issue:492 Volume:10 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Chen Wei-Yu¹²^ORCID,Tsai Yuan-Chin³,Yeh Hsiu-Lien⁴,Suau Florent⁵^ORCID,Jiang Kuo-Ching³,Shao Ai-Ning³,Huang Jiaoti⁶,Liu Yen-Nien³^ORCID

Affiliation:

1. Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan.

2. Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

3. Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

4. Institute of Information System and Applications, National Tsing Hua University, Hsinchu 30013, Taiwan.

5. Department of Microbiology, Faculty of Pharmacy, Dicle University, Diyarbakir 21280, Turkey.

6. Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.

Abstract

Loss of a TGFβ signaling repressor by androgen deprivation therapy shows how a common treatment for primary prostate cancer may promote metastasis.

Funder

Ministry of Health and Welfare

Ministry of Science and Technology, Taiwan

National Health Research Institutes

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference50 articles.

1. Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

2. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review

3. Review of Exercise Studies in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy Calls for an Aggressive Research Agenda to Generate High-Quality Evidence and Guidance for Exercise As Standard of Care

4. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

5. Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The miRNAs 203a/210‐3p/5001‐5p regulate the androgen/androgen receptor/YAP‐induced migration in prostate cancer cells;Cancer Medicine;2024-08

2. TGFBI promotes proliferation and epithelial–mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR/HIF-1α pathway;Cancer Cell International;2024-07-27

3. Transcription Factors in Prostate Cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches;Genes;2024-04-02

4. Novel prognostic marker TGFBI affects the migration and invasion function of ovarian cancer cells and activates the integrin αvβ3-PI3K-Akt signaling pathway;Journal of Ovarian Research;2024-02-23

5. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance;Cancer Letters;2023-12